Iron chelators as therapeutic agents for the treatment of cancer

Critical Reviews in Oncology/Hematology

Volumn 42, Issue 3, 2002, Pages 267-281

  Richardson, D R ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

Author keywords

311; Cancer; Desferrioxamine; Iron chelators; Iron metabolism; Neoplastic cells; Pyridoxal isonicotinoyl hydrazone

Indexed keywords

2 HYDROXY 1 NAPHTHYLALDEHYDISONICOTINOYLHYDRAZONE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 3 AMINOPYRIDINE 2 CARBOXALDEHYDETHIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; AROYLHYDRAZONE; CARRIER PROTEIN; CHELATING AGENT; DEFEROXAMINE; IRON CHELATE; LIGAND; O TRENSOX; RECEPTOR SUBTYPE; TACHPYRIDINE; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CELL MEMBRANE; CELL METABOLISM; CELL PROLIFERATION; CHELATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG TARGETING; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IRON OVERLOAD; LEUKEMIA; MEMBRANE PERMEABILITY; NEUROBLASTOMA; NONHUMAN; REVIEW; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IRON; IRON CHELATING AGENTS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036269005     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00218-9     Document Type: Review

References (133)

1. Effect of dietary iron deficiency or excess on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea
2. Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma
3. Complexes of gallium(III) and other metal ions and their potential in the treatment of neoplasia
4. Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor
5. Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: Evidence for a threshold model of iron deprivation toxicity
6. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor
7. Iron deprivation and cancer: A view beginning with studies of monoclonal antibodies against the transferrin receptor
8. Demonstration of nitrogen coordination in metal-bleomycin complexes by electron spin-echo envelope spectroscopy
9. The reduction of ribonucleotides
10. Continual presence of oxygen and iron is required for mammalian ribonucleotide reduction: Possible regulation mechanism
11. Enzymology of cancer cells
12. Role of ribonucleotide reductase in expression in the neoplastic program
13. Regulation of ribonucleotide reductase activity and its possible exploitation in chemotherapy
14. Ribonucleotide reductase and cell proliferation
15. Part VII. Chemotherapeutic agents - Cancer chemotherapy
16. Hydroxyurea (NSC-32065) in biological fluids: Dose-concentration relationship
17. Pharmacokinetics and pharmacodynamics of hydroxyurea
18. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY)
19. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents
20. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone
21. The potential of analogues of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents III: The effect of the ligands on molecular targets involved in proliferation
22. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells
23. Function and regulation of transferrin and ferritin
24. Transferrin: Biochemistry, physiology and clinical significance
25. Binding of apotransferrin to K562 cells: Explanation of the transferrin cycle
26. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits tumor cell growth in vitro
27. Modulation of cell surface iron transferrin receptors by cellular density and the state of activation
28. The uptake of iron and transferrin by the human melanoma cell
29. Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate
30. Transferrin receptor-independent uptake of diferric transferrin by human hepatoma cells with antisense inhibition of receptor expression
31. Inhibition of gallium-67 uptake in melanoma by an anti-human transferrin receptor monoclonal antibody
32. Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells: Mechanisms responsible for the specific cytotoxicity of transferrin-gallium
33. Uptake of gallium-67 by human leukemic cells: Demonstration of transferrin receptor-dependent and transferrin receptor-independent mechanisms
34. Evaluation of transferrin and gallium-pyridoxal isonicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate
35. Iron withholding a defense against infection and neoplasia
36. Molecular cloning of transferrin receptor 2: A new member of the transferrin receptor-like family
37. Transferrin receptor 2-α supports cell growth both in iron-chelated cultured cells and in vivo
38. Transferrin receptor 2: Continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis
39. The mechanisms of iron uptake by rat fetal hepatocytes
40. Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators and metabolic probes on transferrin and iron uptake
41. Cloning and characterization of a mammalian proton-coupled metal-ion transporter
42. Microcytic anemia mice have a mutation in Nramp2, a candidate iron transporter gene
43. Low molecular weight intracellular iron transport compounds
44. Transferrin and iron distribution in subcellular fractions of K562 cells in early stages of transferrin endocytosis
45. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: Examination of the intermediates of iron metabolism
46. Copper chaperones: Function, structure and copper-binding properties
47. The ferritins: Molecular properties, iron storage function and cellular regulation
48. Iron chelators as effective anti-proliferative agents
49. Control of cell proliferation by myc
50. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-myc
51. Molecular control of vertebrate iron metabolism: MRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress
52. The effect of intracellular iron concentration and nitrogen monoxide on Nramp2 expression and non-transferrin-bound iron uptake
53. Molecular characterization of a second iron-responsive element binding protein, iron-regulatory protein 2, Structure, function, and post-translational regulation
54. Iron regulates the intracellular degradation of iron regulatory protein 2 by the proteasome
55. Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene
56. Sequential expression of genes involved in human human T lymphocyte growth and differentiation
57. Effects of agents that inhibit cellular iron incorporation on bladder cell proliferation
58. Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells
59. Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium/iron uptake, increased activity of iron regulatory protein-1, and decreased ferritin production
60. Transferrin promotion of 67Ga and 59Fe uptake by cultured mouse myeloma cells
61. Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor
62. HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation
63. Identification of a hypoxia response element in the transferrin receptor gene
64. Transferrin receptor induction by hypoxia, HIF-1 mediated transcriptional activation and cell specific post-transcriptional regulation
65. Iron chelating therapy and the treatment of thalassemia
66. Orally effective iron chelators for the treatment of iron overload disease: The case for a further look at pyridoxal isonicotinoyl hydrazone (PIH) and its analogs
67. The biochemistry of deferoxamine and its relation to iron metabolism
68. Role of desferrioxamine in tumor therapy
69. Antineuroblastoma activity of desferrioxamine in human cell lines
70. Deferoxamine inhibition of human neuroblastoma viability and proliferation
71. Effects of a single course of deferoxamine in neuroblastoma patients
72. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECat): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma
73. Deferoxamine (D) followed by cytoxan (C), etoposide (E), carboplatin (Ca), thio-TEPA (T), induction regimen in advanced neuroblastoma
74. Neuroblastomas contain iron-rich ferritin
75. In vivo and in vitro effects of desferrioxamine in neonatal acute leukaemia
76. Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: In vitro and in vivo studies
77. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice
78. Desferrioxamine prolongs survival of mice with L1210 lymphocytic leukaemia
79. Iron-dependent changes in cellular energy metabolism: Influence on citric acid cycle and oxidative phosphorylation
80. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts
81. Deferoxamine in children with recurrent neuroblastoma
82. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell
83. Studies of the reaction of 2-formylpyridine thiosemicarbazone and its iron and copper complexes with biological systems
84. Inhibition of the growth of sarcoma 180 ascites cells by combinations of inhibitors of nucleic acid biosynthesis and the cupric chelate of kethoxal bis-(thiosemicarbazone)
85. Mechanism of inhibition of ribonucleoside diphosphate reductase by α-(N)-heterocyclic aldehyde thiosemicarbazones
86. Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone
87. Synergistic interaction of kethoxal bis(thiosemicarbazone) and cupric ions in sarcoma 180
88. Metabolic effects of copper in intact cells: Comparative activity of cupric chloride and kethoxal bis(thiosemicarbazone)
89. Metabolic effects of zinc in intact cells-comparative studies of zinc chloride and the zinc chelate of kethoxal bis(thiosemicarbazone)
90. Studies on the mode of action of the copper(II) chelate of 2-keto-3-ethoxybutyraldehyde bis(thiosemicarbazone)
91. The chemistry and biological activity of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones
92. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity
93. The carcinostatic activity of alpha-(N) heterocyclic carboxaldehyde thiosemicarbazones, I. Isoquinoline-1-carboxaldehyde thiosemicarbazone
94. Chelating substances
95. Studies of the anti-neoplastic activity and metabolism of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones in dogs and mice
96. Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone
97. Clinical trial of 5-hydroxypicolinaldehyde thiosemicarbazone (5-HP: NSC-107392), with special reference to its Fe chelating properties
98. Synthesis and antitumor evaluation of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone
99. Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxlaldehyde thiosemicarbazones
100. Effect of iron chelating agents on inhibitors of ribonucleotide reductase
101. Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo
102. Mobilization of iron from reticulocytes, identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent
103. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents
104. Nicotinoyl and isonicotinoyl hydrazones of pyridoxal
105. Effective iron chelation following oral adminstration of an isoniazid pyridoxal hydrazone
106. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone
107. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture
108. Evaluation of the iron chelation potential of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture
109. Cytotoxic chelators and chelates 1. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone
110. Inhibition of the growth of cultured cells and an implanted fibrosarcoma by aroylhydrazone analogs of the Gly-His-Lys-Cu(II) complex
111. Iron chelators of the pyridoxal isonicotinoyl hydrazone class III. Formation constants with calcium(II), magnesium(II) and zinc(II)
112. Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part 2. Formation constants with iron(III) and iron(II)
113. Pyridoxal isonicotinoyl hydrazone (PIH), a synthetic ion chelating agent
114. Crystal and molecular structure of 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: An iron chelator with anti-proliferative activity
115. The synthesis, crystal and molecular structure, and oxidation state of iron complex from pyridoxal isonicotinoyl hydrazone and ferrous sulphate
116. P53 in chronic myeloid leukemia cell lines
117. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines
118. Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562
119. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage
120. Structure, function and regulation of p63 and p73
121. Regulation and function of the p53-related proteins: Same family, different rules
122. Two new p73 splice variants, gamma and delta, with different transcriptional activity
123. Promoter specificity and stability control of the p53-related protein p73
124. Effect of iron chelators with potent anti-proliferative activity on the expression of molecules involved in cell cycle progression and proliferation
125. Development of novel aroylhydrazone ligands for iron chelation therapy: The 2-pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) analogues
126. Stabilization of wild-type p53 by hypoxia-inducible factor 1α
127. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status
128. Up-regulation of hypoxia-inducible factor-1α is not sufficient for hypoxic/anoxic p53 induction
129. Tumor cell cytotoxicity of a novel metal chelator
130. Iron chelation in cancer therapy
131. Chemistry of novel redox-active Fe(II) chelators and their cytotoxic effects
132. Anti-proliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines